What is Sava?
Sava is a pioneering biosensing technology company dedicated to transforming how individuals interact with their health. By developing advanced, non-invasive sensors that operate just below the skin, the company provides a seamless interface for continuous health tracking. This approach addresses the growing market demand for affordable, real-time health insights, moving away from traditional, episodic medical testing. Sava's market position is defined by its ability to integrate sophisticated scientific research with user-centric design, effectively democratizing access to vital health information and empowering users to make informed, data-driven decisions about their well-being.
How much funding has Sava raised?
Sava has raised a total of $27M across 2 funding rounds:
Angel/Seed
$8M
Series A
$19M
Angel/Seed (2024): $8M with participation from EXOR and Balderton
Series A (2025): $19M led by Exceptional Ventures, True Capital, Italian Founders Fund, Balderton, JamJar Investments, Athletico Ventures, and Norrsken Vc
Key Investors in Sava
Balderton
A London-based venture capital firm that raises dedicated funds to invest in early-stage, high-growth technology companies across Europe, typically leading Seed and Series A rounds.
Norrsken Vc
Europe's leading early-stage impact investor, focusing on companies that address significant global challenges while achieving substantial business growth.
EXOR
An investment holding company that makes medium to long-term investments across diverse sectors including financial services, real estate, and industrial technology.
What's next for Sava?
Following this major enterprise-level funding, Sava is poised to accelerate its research and development pipeline and scale its operational footprint. The strategic capital will likely be deployed to refine its biosensing hardware, navigate regulatory pathways, and expand its market reach. As the company transitions from its early-stage development phase into a more mature scaling cycle, the focus will shift toward commercialization and establishing partnerships within the broader healthcare ecosystem. With the support of its high-profile investor base, Sava is well-equipped to navigate the complexities of the health-tech landscape and deliver on its promise of ubiquitous, real-time health monitoring.
See full Sava company page
